{
  "actions": [
    {
      "acted_at": "2025-02-21",
      "action_code": "Intro-H",
      "references": [],
      "text": "Introduced in House",
      "type": "action"
    },
    {
      "acted_at": "2025-02-21",
      "action_code": "H11100",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "status": "REFERRED",
      "text": "Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.",
      "type": "referral"
    },
    {
      "acted_at": "2025-02-21",
      "action_code": "H11100",
      "committees": [
        "HSWM"
      ],
      "references": [],
      "text": "Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.",
      "type": "referral"
    }
  ],
  "amendments": [],
  "bill_id": "hr1476-119",
  "bill_type": "hr",
  "by_request": false,
  "committee_reports": [],
  "committees": [
    {
      "activity": [
        "Referred To"
      ],
      "committee": "House Ways and Means",
      "committee_id": "HSWM"
    },
    {
      "activity": [
        "Referred To"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF"
    }
  ],
  "congress": "119",
  "cosponsors": [
    {
      "bioguide_id": "D000230",
      "district": "1",
      "name": "Davis, Donald G.",
      "original_cosponsor": true,
      "sponsored_at": "2025-02-21",
      "state": "NC",
      "title": "Rep.",
      "withdrawn_at": null
    },
    {
      "bioguide_id": "K000405",
      "district": "13",
      "name": "Knott, Brad",
      "original_cosponsor": false,
      "sponsored_at": "2025-06-03",
      "state": "NC",
      "title": "Rep.",
      "withdrawn_at": null
    },
    {
      "bioguide_id": "M001210",
      "district": "3",
      "name": "Murphy, Gregory F.",
      "original_cosponsor": true,
      "sponsored_at": "2025-02-21",
      "state": "NC",
      "title": "Rep.",
      "withdrawn_at": null
    },
    {
      "bioguide_id": "P000608",
      "district": "50",
      "name": "Peters, Scott H.",
      "original_cosponsor": true,
      "sponsored_at": "2025-02-21",
      "state": "CA",
      "title": "Rep.",
      "withdrawn_at": null
    },
    {
      "bioguide_id": "R000603",
      "district": "7",
      "name": "Rouzer, David",
      "original_cosponsor": false,
      "sponsored_at": "2025-05-05",
      "state": "NC",
      "title": "Rep.",
      "withdrawn_at": null
    }
  ],
  "enacted_as": null,
  "history": {
    "active": false,
    "awaiting_signature": false,
    "enacted": false,
    "vetoed": false
  },
  "introduced_at": "2025-02-21",
  "number": "1476",
  "official_title": "To amend title XVIII of the Social Security Act to provide a phase-in for plasma-derived products under the manufacturer discount program.",
  "popular_title": null,
  "related_bills": [
    {
      "bill_id": "s694-119",
      "identified_by": "CRS",
      "reason": "identical",
      "type": "bill"
    }
  ],
  "short_title": "PLASMA Act",
  "sponsor": {
    "bioguide_id": "H001067",
    "district": "9",
    "name": "Hudson, Richard",
    "state": "NC",
    "title": "Rep.",
    "type": "person"
  },
  "status": "REFERRED",
  "status_at": "2025-02-21",
  "subjects": [
    "Blood and blood diseases",
    "Drug therapy",
    "Health",
    "Health care costs and insurance",
    "Manufacturing",
    "Medicare",
    "Prescription drugs"
  ],
  "subjects_top_term": "Health",
  "summary": {
    "as": "Introduced in House",
    "asOf": "2025-02-21",
    "date": "2025-08-05T21:30:36Z",
    "text": "Preserving Life-saving Access to Specialty Medicines in America Act or the PLASMA Act\n\nThis bill phases-in certain price adjustments for plasma-derived products under the Medicare prescription drug benefit's Manufacturer Discount Program.\n\nCurrent law requires manufacturers of covered drugs under the Medicare prescription drug benefit to provide a 10% discount for covered drugs during the initial coverage phase (i.e., before a beneficiary reaches the out-of-pocket spending threshold) and a 20% discount during the catastrophic coverage phase (i.e., after a beneficiary reaches the out-of-pocket spending threshold).\u00a0\n\nThe bill phases-in discounts for plasma-derived products over several years, starting with a 1% discount in 2026 for both the initial and catastrophic coverage phases, and ending with a 10% discount beginning in 2030 for the initial coverage phase and a 20% discount beginning in 2032 for the catastrophic coverage phase."
  },
  "titles": [
    {
      "as": null,
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "PLASMA Act",
      "type": "display"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "PLASMA Act",
      "type": "short"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Preserving Life-saving Access to Specialty Medicines in America Act",
      "type": "short"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "To amend title XVIII of the Social Security Act to provide a phase-in for plasma-derived products under the manufacturer discount program.",
      "type": "official"
    }
  ],
  "updated_at": "2025-11-19T03:06:44Z",
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/119/hr/BILLSTATUS-119hr1476.xml"
}